Extended indication

Extension of indication to include treatment of severe postpartum haemorrhage

Therapeutic value

No estimate possible yet

Registration phase

Registration application pending

Product

Active substance

Eptacog alfa (activated)

Domain

Cardiovascular diseases

Reason of inclusion

Indication extension

Main indication

Other non-oncological hematological medications

Extended indication

Extension of indication to include treatment of severe postpartum haemorrhage

Proprietary name

NovoSeven

Manufacturer

Novo Nordisk

Route of administration

Intravenous

Therapeutical formulation

Injection

Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)

Submission date

October 2021

Expected Registration

August 2022

Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.